The Cancer Letter

Inside information on cancer research and drug development

In Brief

The Parker Institute for Cancer Immunotherapy awards up to $2.9M to eight early-career investigators

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Parker Institute for Cancer Immunotherapy is recognizing its seventh Early Career Researcher Awards class—eight exceptional graduate and postdoctoral researchers from the PICI Network—a consortium of the world’s leading cancer research institutions, who will share up to $2.9 million total in awards to support their research.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Keytruda combination improves OS for HER2-positive advanced gastric cancer in phase III trial

The phase III KEYNOTE-811 trial evaluating Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with trastuzumab and fluoropyrimidine- and platinum-containing chemotherapy met its dual primary endpoint of overall survival for the first-line treatment of patients with human epidermal growth factor receptor 2-positive locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.
Table of Contents

Login

Site license subscribers:
Log in with your IP | Register a sponsored account